{"id":"NCT01734785","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes","officialTitle":"A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-08","primaryCompletion":"2015-03-23","completion":"2015-03-23","firstPosted":"2012-11-28","resultsPosted":"2016-04-18","lastUpdate":"2024-09-19"},"enrollment":607,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Linagliptin","otherNames":[]},{"type":"DRUG","name":"Empagliflozin + Linagliptin","otherNames":[]},{"type":"DRUG","name":"Empagliflozin + Linagliptin","otherNames":[]},{"type":"DRUG","name":"Empagliflozin + Linagliptin","otherNames":[]},{"type":"DRUG","name":"Empagliflozin placebo + Linagliptin placebo","otherNames":[]},{"type":"DRUG","name":"Empagliflozin + Linagliptin","otherNames":[]}],"arms":[{"label":"Linagliptin","type":"ACTIVE_COMPARATOR"},{"label":"Empagliflozin + Linagliptin low dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin + Linagliptin high dose","type":"EXPERIMENTAL"}],"summary":"This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.","primaryOutcome":{"measure":"HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Empagliflozin 25 mg","deltaMin":-0.56,"sd":0.08},{"arm":"Empagliflozin 10 mg","deltaMin":-0.65,"sd":0.08},{"arm":"Placebo","deltaMin":0.14,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Australia","Brazil","Canada","El Salvador","France","New Zealand","Norway","South Korea","Spain","Taiwan"]},"refs":{"pmids":["27913576"],"seeAlso":["https://www.mystudywindow.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":110},"commonTop":["Urinary tract infection","Nasopharyngitis","Headache","Lipase increased","Hyperglycaemia"]}}